McInnes 2009.

Methods	This was a randomised, placebo‐controlled trial (GO‐REVEAL study), with 405 participants.
Participants	Inclusion criteria of the trial Psoriatic arthritis participants with 3 swollen and 3 tender joints and active plaque psoriasis (at least 1 lesion at least 2 cm in diameter)
Interventions	Subcutaneous placebo Golimumab 50 mg Golimumab 100 mg The interventions were administered every 4 weeks.
Outcomes	Outcomes of the trial The single worst psoriasis‐affected nail (target) was assessed using the Nail Psoriasis Severity Index (NAPSI). The Nail Physician's Global Assessment (PGA; 1 to 5; 1 = absence of; 5 = very severe) evaluated all fingernails.
Notes	This was a conference publication.